BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kalambokis GN, Oikonomou A, Christou L, Kolaitis NI, Tsianos EV, Christodoulou D, Baltayiannis G. von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia. J Hepatol 2016;65:921-8. [PMID: 27297911 DOI: 10.1016/j.jhep.2016.06.002] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Eidelberg A, Kirubakaran R, Nair SC, Eapen CE, Elias E, Goel A. Systematic review: role of elevated plasma von-Willebrand factor as predictor of mortality in patients with chronic liver disease. Eur J Gastroenterol Hepatol 2019;31:1184-91. [PMID: 31498279 DOI: 10.1097/MEG.0000000000001491] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
2 Noronha Ferreira C, Marinho RT, Cortez-Pinto H, Ferreira P, Dias MS, Vasconcelos M, Alexandrino P, Serejo F, Pedro AJ, Gonçalves A, Palma S, Leite I, Reis D, Damião F, Valente A, Xavier Brito L, Baldaia C, Fatela N, Ramalho F, Velosa J. Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: A prospective study. Liver Int 2019;39:1459-67. [PMID: 31021512 DOI: 10.1111/liv.14121] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 9.5] [Reference Citation Analysis]
3 Tripodi A, D'ambrosio R, Padovan L, Tosetti G, Aghemo A, Primignani M, Chantarangkul V, Peyvandi F, Colombo M. Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis. Liver Int 2017;37:1295-303. [DOI: 10.1111/liv.13374] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
4 Mandorfer M, Schwabl P, Paternostro R, Pomej K, Bauer D, Thaler J, Ay C, Quehenberger P, Fritzer-Szekeres M, Peck-Radosavljevic M, Trauner M, Reiberger T, Ferlitsch A; Vienna Hepatic Hemodynamic Lab. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. Aliment Pharmacol Ther 2018;47:980-8. [PMID: 29377193 DOI: 10.1111/apt.14522] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 11.3] [Reference Citation Analysis]
5 van Dievoet MA, Eeckhoudt S, Stephenne X. Primary Hemostasis in Chronic Liver Disease and Cirrhosis: What Did We Learn over the Past Decade? Int J Mol Sci 2020;21:E3294. [PMID: 32384725 DOI: 10.3390/ijms21093294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Takaya H, Namisaki T, Shimozato N, Kaji K, Kitade M, Moriya K, Sato S, Kawaratani H, Akahane T, Matsumoto M, Yoshiji H. ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma. World J Gastrointest Oncol. 2019;11:424-435. [PMID: 31139312 DOI: 10.4251/wjgo.v11.i5.424] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 La Mura V, Braham S, Tosetti G, Branchi F, Bitto N, Moia M, Fracanzani AL, Colombo M, Tripodi A, Primignani M. Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis. Clin Gastroenterol Hepatol. 2018;16:1146-1152.e4. [PMID: 29066371 DOI: 10.1016/j.cgh.2017.10.016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
8 Weil D, Pais de Barros JP, Mourey G, Laheurte C, Cypriani B, Badet N, Delabrousse E, Grandclément E, Di Martino V, Saas P, Lagrost L, Thévenot T. Circulating levels of 3-hydroxymyristate, a direct quantification of endotoxaemia in noninfected cirrhotic patients. Liver Int 2019;39:106-14. [PMID: 29931819 DOI: 10.1111/liv.13916] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Burra P, Samuel D, Sundaram V, Duvoux C, Petrowsky H, Terrault N, Jalan R. Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation. J Hepatol 2021;75 Suppl 1:S178-90. [PMID: 34039488 DOI: 10.1016/j.jhep.2021.01.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
10 Joshi N, Kopec AK, Ray JL, Cline-Fedewa H, Groeneveld DJ, Lisman T, Luyendyk JP. Von Willebrand factor deficiency reduces liver fibrosis in mice. Toxicol Appl Pharmacol 2017;328:54-9. [PMID: 28527913 DOI: 10.1016/j.taap.2017.05.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
11 Lisman T, Bos S, Intagliata NM. Mechanisms of enhanced thrombin‐generating capacity in patients with cirrhosis. J Thromb Haemost 2018;16:1128-31. [DOI: 10.1111/jth.14020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
12 Ibrahim EH, Marzouk SA, Zeid AE, Lashen SA, Taher TM. Role of the von Willebrand factor and the VITRO score as predictors for variceal bleeding in patients with hepatitis C-related cirrhosis. Eur J Gastroenterol Hepatol 2019;31:241-7. [PMID: 30281535 DOI: 10.1097/MEG.0000000000001272] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Langholm LL, Manon-Jensen T, Karsdal MA, Bendtsen F, Leeming DJ, Møller S. Enhanced processing of von Willebrand factor reflects disease severity and discriminates severe portal hypertension in cirrhosis. Eur J Gastroenterol Hepatol 2019;31:1040-8. [PMID: 30768435 DOI: 10.1097/MEG.0000000000001380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 O’leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA Clinical Practice Update: Coagulation in Cirrhosis. Gastroenterology 2019;157:34-43.e1. [DOI: 10.1053/j.gastro.2019.03.070] [Cited by in Crossref: 81] [Cited by in F6Publishing: 57] [Article Influence: 40.5] [Reference Citation Analysis]
15 Zou Z, Yan X, Li C, Li X, Ma X, Zhang C, Ju S, Tian J, Qi X. von Willebrand factor as a biomarker of clinically significant portal hypertension and severe portal hypertension: a systematic review and meta-analysis. BMJ Open 2019;9:e025656. [PMID: 31473610 DOI: 10.1136/bmjopen-2018-025656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Simonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation. Am J Gastroenterol. 2020;115:18-40. [PMID: 31895720 DOI: 10.14309/ajg.0000000000000486] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 26.0] [Reference Citation Analysis]
17 Qi T, Zhu C, Lu G, Hao J, He Q, Chen Y, Zhou F, Chen J, Hou J. Elevated D-dimer is associated with increased 28-day mortality in acute-on-chronic liver failure in China: a retrospective study. BMC Gastroenterol 2019;19:20. [PMID: 30704397 DOI: 10.1186/s12876-019-0941-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
18 Stravitz RT. Algorithms for managing coagulation disorders in liver disease. Hepatol Int 2018;12:390-401. [PMID: 30066204 DOI: 10.1007/s12072-018-9886-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
19 Zermatten MG, Fraga M, Calderara DB, Aliotta A, Moradpour D, Alberio L. Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis. JHEP Rep 2020;2:100120. [PMID: 32715285 DOI: 10.1016/j.jhepr.2020.100120] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
20 Lisman T, Porte RJ. Pathogenesis, prevention, and management of bleeding and thrombosis in patients with liver diseases. Res Pract Thromb Haemost 2017;1:150-61. [PMID: 30046685 DOI: 10.1002/rth2.12028] [Cited by in Crossref: 58] [Cited by in F6Publishing: 39] [Article Influence: 14.5] [Reference Citation Analysis]
21 Palyu E, Harsfalvi J, Tornai T, Papp M, Udvardy M, Szekeres-Csiki K, Pataki L, Vanhoorelbeke K, Feys HB, Deckmyn H, Tornai I. Major Changes of von Willebrand Factor Multimer Distribution in Cirrhotic Patients with Stable Disease or Acute Decompensation. Thromb Haemost 2018;118:1397-408. [PMID: 29972862 DOI: 10.1055/s-0038-1661393] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
22 Mandorfer M, Reiberger T, Ferlitsch A; Vienna Hepatic Hemodynamic Lab. Editorial: von Willebrand factor and CRP levels may predict survival in liver cirrhosis-Authors' reply. Aliment Pharmacol Ther 2018;47:1537-8. [PMID: 29878416 DOI: 10.1111/apt.14624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Blasi A, Cardenas A. Invasive Procedures in Patients with Cirrhosis: A Clinical Approach Based on Current Evidence. Clin Liver Dis 2021;25:461-70. [PMID: 33838861 DOI: 10.1016/j.cld.2021.02.001] [Reference Citation Analysis]
24 Sigal SH, Sherman Z, Jesudian A. Clinical Implications of Thrombocytopenia for the Cirrhotic Patient. Hepat Med. 2020;12:49-60. [PMID: 32341665 DOI: 10.2147/hmer.s244596] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
25 Bitto N, Liguori E, La Mura V. Coagulation, Microenvironment and Liver Fibrosis. Cells. 2018;7:pii: E85. [PMID: 30042349 DOI: 10.3390/cells7080085] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
26 Sigon G, D'Ambrosio R, Clerici M, Pisano G, Chantarangkul V, Sollazzi R, Lombardi R, Peyvandi F, Lampertico P, Fargion S, Tripodi A, Fracanzani AL. Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis. Liver Int 2019;39:2309-16. [PMID: 31419372 DOI: 10.1111/liv.14213] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
27 Tripodi A, Fracanzani AL, Chantarangkul V, Primignani M, Fargion S. Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol. 2017;66:248-250. [PMID: 27769731 DOI: 10.1016/j.jhep.2016.09.025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
28 Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. Gastroenterology 2019; 156: 1582-1599. e1. [PMID: 30771355 DOI: 10.1053/j.gastro.2019.01.265] [Cited by in Crossref: 79] [Cited by in F6Publishing: 54] [Article Influence: 39.5] [Reference Citation Analysis]
29 Pradhan-Sundd T, Gudapati S, Kaminski TW, Ragni MV. Exploring the Complex Role of Coagulation Factor VIII in Chronic Liver Disease. Cell Mol Gastroenterol Hepatol 2021;12:1061-72. [PMID: 33705963 DOI: 10.1016/j.jcmgh.2021.02.014] [Reference Citation Analysis]
30 Kukla M, Waluga M, Żorniak M, Berdowska A, Wosiewicz P, Sawczyn T, Bułdak RJ, Ochman M, Ziora K, Krzemiński T, Hartleb M. Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis. World J Gastroenterol 2017;23:2613-24. [PMID: 28465646 DOI: 10.3748/wjg.v23.i14.2613] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
31 Basili S, Raparelli V, Napoleone L, Talerico G, Corazza GR, Perticone F, Sacerdoti D, Andriulli A, Licata A, Pietrangelo A, Picardi A, Raimondo G, Violi F; PRO-LIVER Collaborators. Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study. Am J Gastroenterol 2018;113:368-75. [PMID: 29257146 DOI: 10.1038/ajg.2017.457] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
32 Zhang X, Thomas C, Schiano TD, Thung SN, Ward SC, Fiel MI. Aberrant von Willebrand factor expression of sinusoidal endothelial cells and quiescence of hepatic stellate cells in nodular regenerative hyperplasia and obliterative portal venopathy. Histopathology 2020;76:959-67. [PMID: 31994248 DOI: 10.1111/his.14083] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Freed J, Bauer KA. Thrombophilia. Consultative Hemostasis and Thrombosis. Elsevier; 2019. pp. 242-65. [DOI: 10.1016/b978-0-323-46202-0.00014-5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Adam EH, Möhlmann M, Herrmann E, Schneider S, Zacharowski K, Zeuzem S, Weber CF, Weiler N. Assessment of hemostatic profile in patients with mild to advanced liver cirrhosis. World J Gastroenterol 2020;26:2097-110. [PMID: 32536777 DOI: 10.3748/wjg.v26.i17.2097] [Reference Citation Analysis]
35 Intagliata NM, Argo CK, Stine JG, Lisman T, Caldwell SH, Violi F; faculty of the 7th International Coagulation in Liver Disease. Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference. Thromb Haemost. 2018;118:1491-1506. [PMID: 30060258 DOI: 10.1055/s-0038-1666861] [Cited by in Crossref: 69] [Cited by in F6Publishing: 53] [Article Influence: 23.0] [Reference Citation Analysis]